# Serum proteomic profiling of physical activity reveals CD300LG as a novel exerkine with a potential causal link to glucose homeostasis

Sindre Lee-Ødegård[1,2], Marit Hjorth[3*], Thomas Olsen[3*], Gunn-Helen Moen[2,4,5,7], Emily Daubney[4], David M Evans[4-6], Andrea Hevener[8], Aldons Jake Lusis[9,10], Mingqi Zhou[11], Marcus Michael Seldin[11], Hooman Allayee[12,13], James R. Hilser[12,13], Jonas Krag Viken[2], Hanne L. Gulseth[14], Frode Norheim[3], Christian A. Drevon[15], Kåre I. Birkeland[1,2]

[1]Department of Endocrinology, Morbid obesity and Preventive Medicine, Oslo University Hospital, Norway.

[2]Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.

[3]Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway.

[4]Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia

[5]The Frazer Institute, The University of Queensland, 4102, Woolloongabba, QLD, Australia.

[6]MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

[7]Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.

[8]Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.

[9]Department of Human Genetics, UCLA, Los Angeles, CA, USA.

[10]Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

[11]Department of Biological Chemistry, University of California, Irvine, Irvine, USA.

[12]Departments of Population & Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, USA.

[13]Department of Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA.

[14]Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Norway.

[15]Vitas Ltd, Oslo Science Park, Oslo, Norway.

*Shared second authorship

Correspondence: Sognsvannsveien 9, Domus Medica, 0372 Oslo, Norway. Email: sindre.lee@medisin.uio.no. Phone: +47 22 85 13 92. Fax: + 47 22 85 03 01.

## Abstract

**Background:** Physical activity has been associated with preventing the development of type 2 diabetes and atherosclerotic cardiovascular disease. However, our understanding of the precise molecular mechanisms underlying these effects remains incomplete and good biomarkers to objectively assess physical activity are lacking.

**Methods:** We analyzed 3072 serum proteins in 26 men, normal weight or overweight, undergoing 12 weeks of a combined strength and endurance exercise intervention. We estimated insulin sensitivity with hyperinsulinemic euglycemic clamp, maximum oxygen uptake, muscle strength, and used MRI/MRS to evaluate body composition and organ fat depots. Muscle and subcutaneous adipose tissue biopsies were used for mRNA sequencing. Additional association analyses were performed in samples from up to 47,747 individuals in the UK Biobank, as well as using 2-sample Mendelian randomization and mice models.

**Results:** Following 12 weeks of exercise intervention, we observed significant changes in 283 serum proteins. Notably, 66 of these proteins were elevated in overweight men and positively associated with liver fat before the exercise regimen, but were normalized after exercise. Furthermore, for 19.7% and 12.1% of the exercise-responsive proteins, corresponding changes in mRNA expression levels in muscle and fat, respectively, were shown. The protein CD300LG displayed consistent alterations in blood, muscle, and fat. Serum CD300LG exhibited positive associations with insulin sensitivity, and to angiogenesis-related gene expression in both muscle and fat. Furthermore, serum CD300LG was positively associated with physical activity and negatively associated with glucose levels in the UK Biobank. In this sample, the association between serum CD300LG and physical activity was significantly stronger in men than in women. Mendelian randomization analysis suggested potential causal relationships between levels of serum CD300LG and fasting glucose, 2-hour glucose after an oral glucose tolerance test, and HbA1c. Additionally, Cd300lg responded to exercise in a mouse model, and we observed signs of impaired glucose tolerance in male, but not female, *Cd300lg* knockout mice.

**Conclusion:** Our study identified several novel proteins in serum whose levels change in response to prolonged exercise and were significantly associated with body composition, liver fat, and glucose homeostasis. Serum CD300LG increased with physical activity and is a

potential causal link to improved glucose levels. CD300LG may be a promising exercise biomarker and a therapeutic target in type 2 diabetes.

## Introduction

Physical activity is a cornerstone in the prevention and treatment of several chronic diseases like obesity, non-alcoholic fatty liver disease (NAFLD), atherosclerotic vascular disease, and type 2 diabetes mellitus [1]. Both acute and long-term exercise may enhance insulin sensitivity and thereby improve glucose tolerance [2]. Both resistance and endurance exercises enhance insulin sensitivity, although the most pronounced effect is observed when combining these training modalities [3].

Metabolic adaptations to exercise encompass intricate inter-organ communication facilitated by molecules referred to as exerkines [4-7]. These exerkines are secreted from various tissues and include a variety of signal molecules released in response to acute and/or long-term exercise with endocrine, paracrine and/or autocrine functions [4,5]. Although there has been considerable emphasis on exerkines originating from skeletal muscle (SkM) [8,9], it is also known that exerkines can originate from organs such as white [6,10,11] and brown adipose tissue [12] or the liver [13]. The established *bona fide* exerkine, interleukin-6 (IL6), is released during muscle contractions, contributing to improved overall glucose homeostasis [4,14]. In addition, a range of other exerkines are recognized, including IL7 [15], 12,13-diHOME [12], myonectin [16], myostatin [17,18], METRNL [19], CSF1 [8], decorin [20], SFRP4 [10], fetuin-A [13,21], and ANGPTL4 [22,23], among many others [5].

Extensive screening aimed at discovering novel exercise responsive blood proteins have faced considerable challenges, primarily due to the technical challenges in quantifying the blood proteome on a large scale. However, recent advances in multi-plex technology, such as the proximity extension assay (PEA), have made it possible to quantify more than 3000 proteins in blood samples more reliably than traditional untargeted mass spectrometry (https://olink.com/application/pea). Some recent studies have used other proteomic platforms, such as aptamer-based techniques (https://somalogic.com/somascan-platform/), to show that acute and long-term aerobic exercise affected several hundred serum proteins

[24-28], but the downstream causal effects of such changes on clinical phenotypes are not known. Furthermore, no studies have used the PEA technology to identify exerkines potentially underlying the mechanisms through which long-term physical activity, including strength exercise, enhances glucose homeostasis.

We performed the 'physical activity, myokines and glucose metabolism' (MyoGlu) study [29], which was a controlled clinical trial aiming to identify novel secreted factors ('exerkines') that may serve as links between physical activity and glucose metabolism. We conducted a comprehensive serum screening of 3072 proteins in normal weight and overweight men both before and after combined endurance and strength exercise. Rigorous phenotyping was carried out, including hyperinsulinemic euglycemic clamping, assessments of maximum oxygen uptake, maximum muscle strength, and ankle-to-neck MRI/MRS scans.

Exerkines identified with potential effects on glucose homeostasis in the MyoGlu study were subsequently subject to analysis across several external data sets. Using data from 47,747 participants in the UK Biobank [30], we assessed correlations between candidate proteins and estimates of physical activity and glucometabolic outcomes. These associations were then tested for causality using Mendelian randomization (MR). Exerkines of interest were also assessed in a knockout mouse model and in a exercise mouse model to further assess potential links with glucose homeostasis.

## Results

### Cohort characteristics

We studied 26 male participants, including 13 with normal weight, and another 13 with overweight, as described previously [29]. They were subjected to 12-weeks of high-intensity resistance and endurance exercise (Figure 1). The overweight participants had lower glucose tolerance and insulin sensitivity compared to the normal weight participants (Supplementary Table 1). After the 12-week intervention, body fat mass decreased and lean body mass increased, together with significant improvements in insulin sensitivity (~40%), maximum oxygen uptake and muscle strength in both groups (Supplementary Table 1).




***Figure 1. Study overview.*** *We recruited sedentary men with either normal weight or overweight for deep phenotyping before and after a prolonged exercise intervention. Multi-omic analyses, including serum proteomics, clinical traits and muscle and fat transcriptomics identified changed proteins and potential exerkines. Candidate exerkines were subsequently analyzed in serum samples from the UK biobank and tested for associations with physical activity and glucometabolic traits. Top candidates were then subjected to Mendelian randomization and investigated in a mouse exercise model and in a mouse knock-out model to assess casual links between exerkines and glucometabolic traits.*

**Serum proteome responses to prolonged exercise**

Recognizing that circulating proteins could mediate exercise-induced metabolic improvements, we next investigated alterations in the serum proteome in response to the 12-week intervention using PEA technology. Of the 3072 proteins quantified, we detected increased serum concentrations of 126 proteins, and decreased serum concentrations of 157 proteins following the 12-week intervention, at a false discovery rate (FDR) below 5% (Figure 2 A-C; Supplementary Table 2-4). Among these, 20 proteins increased exclusively in normal weight men, whereas 19 proteins increased exclusively in overweight men (Figure 2 D). Four proteins were uniquely reduced in normal weight men, and 66 proteins were uniquely reduced in overweight men (Figure 2 E).




***Figure 2. Serum proteomic responses to prolonged exercise.*** *(A) A volcano plot showing responses in all participants. The X-axis shows $log_2$(fold-changes) and the Y-axis shows negative $log_{10}$(Q-values). The red dots indicate statistical significance (Q<0.05). Only the top 3 up/down-regulated proteins are annotated. (B-C) Similar to A, but in normal weight and overweight men only. (D-E) Venn diagrams of the significant change in proteins shown in A-C. NPX = normalized protein expression. Q = P-values corrected using Benjamini-Hochberg's method. NW = normal weight. OW = overweight.*

Several of the exercise-responsive proteins had potential roles in muscle adaptation and metabolism. For example, platelet-derived growth factor subunit B (PDGFB) and IL7, are both myokines with potential effects on muscle differentiation [15,31]. Further, fibroblast growth factor-binding protein 3 (FGFBP3) may influence running capacity [32] and muscle strength [33]. NADH-cytochrome b5 reductase 2 (CYB5R2) can preserve SkM mitochondria function in aging mice [34]. FGFBP3 and switch-associated protein 70 (SWAP70) may protect against weight gain [35] and cardiac hypertrophy [36], respectively. Finally, dual specificity protein phosphatase 13 isoform A (DUSP13A) is highly specific to SkM [37], making it a potential novel muscle-specific marker for long-term exercise. Detailed results for 2885 proteins in response to prolonged exercise are shown in Supplementary Table 2.

**A proteomic liver fat signature in overweight men**

In response to the 12-week exercise intervention, a larger number of serum proteins responded in overweight men than in normal weight men (Figure 2 B-C). In particular, 66 proteins decreased in serum after 12 weeks in overweight men (Figure 2 E). Gene ontology analyses revealed known pathways only for the proteins that decreased in overweight men (Figure 3 A-B), and one of the most enriched pathways is related to metabolism of organic acids (Figure 3 C). A key driver analysis of the 66 proteins identified SLC22A1, a hepatocyte transporter related to liver fat content (Figure 3 D). Furthermore, the 66 proteins also displayed a 24% overlap with a known human serum proteomic signature of non-alcoholic fatty liver disease (NAFLD; Figure 3 E) [38], but no common proteins with signatures of specific liver cells (The Human Liver Cell Atlas: [39]). Baseline serum protein concentrations in the identified signature of 66 proteins were higher among men with overweight compared to those with normal weight, but were reduced or normalized in overweight men following prolonged exercise (Figure 3 F). Using principal component analysis of the 66 proteins, the first component correlated positively to liver fat content at baseline (Figure 3 G), but not after prolonged exercise (Figure 3 H). Similarly, the first component also correlated positively with several liver-related markers at baseline (Figure 3 L) and negatively to insulin sensitivity at baseline (Figure 3 I), but not after prolonged exercise (Figure 3 J). The first component mediated 37% of the association between baseline insulin sensitivity and liver fat content (Figure 3 K). We observed no enrichments for the remaining proteins (Figure 3 A-B).



***Figure 3. A serum proteomic liver fat signature.*** *(A) No up-regulated proteins after prolonged exercise overlapped with known pathways. (B) Only the 66 down-regulated proteins in the OW group overlapped with known pathways. (C) Top 10 gene sets overlapping with these 66 proteins. (D) SLC22A1 is a key driver among these 66 proteins. (E) These 66 proteins overlapped with a known human serum proteomic non-alcoholic fatty liver disease signature from Govaere et al [38]. (F) The down-regulated proteins in the OW group were elevated in OW vs. NW at baseline but normalized in the OW group after prolonged exercise. The principal component of these 66 proteins correlated with (G) liver fat content at baseline, but (H) not after prolonged exercise, with (I) the clamp M value at baseline, but (J) not after prolonged exercise. (K) The principal component (PC) of these 66 proteins mediated 36.9% of the association between liver fat and M. (L) The principal component of these 66 proteins correlated with several liver-related markers at baseline, but not after prolonged exercise except for ASAT and ALAT (white = non-significant, red/blue = significant). *p<0.05 and **p<0.01.*

**Secretory proteins**

Among the 96 up-regulated and 110 down-regulated serum proteins responding to the 12-week exercise intervention (Figure 2 D-E), 37 are curated secretory proteins, and another 46 proteins are predicted as highly likely secretory proteins (Figure 4 A-C). We assessed the corresponding mRNA responses in SkM and subcutaneous white adipose tissue (ScWAT) following the 12-week intervention (Figure 4 A-C). In total, 19.7 % of the serum secretory proteins displayed a directionally consistent significant change mRNA levels in SkM, whereas 12.1 % of the serum secretory proteins exhibited a corresponding mRNA response in ScWAT (Figure 4 C). *COL1A1* was the most responsive SkM mRNA that also had a corresponding increase in serum COL1A1 after prolonged exercise (Figure 4 D-E). *CCL3* was the most responsive ScWAT mRNA that also had a corresponding decrease in serum after prolonged exercise (Figure 4 F-G). To prioritize proteins for follow-up analyses, we focused on SMOC1 and CD300LG, which had similar exercise responses in blood, SkM and ScWAT (Figure 4 H). SMOC1 is a known hepatokine with effects on insulin sensitivity in mice [40], but probably with no causal link to insulin sensitivity in humans [40,41]. Thus, we focused on CD300LG in subsequent analyses.




***Figure 4. Comparison of secretory protein responses to prolonged exercise in blood with corresponding mRNA levels in skeletal muscle and adipose tissue.*** *(A) mRNA levels in skeletal muscle and (B) adipose tissue for proteins that responded significantly to prolonged exercise. (C) A heatmap of $log_2$(fold-changes) in blood, skeletal muscle and adipose tissue. (D) The most responding mRNA in skeletal muscle, and (E) the response in the blood protein. (F) The most responding mRNA in adipose tissue, and (G) the response in the blood. (H-I) Venn diagrams of significant changes in blood, skeletal muscle and adipose tissue. FC = fold-change. SkM = skeletal muscle. ScWAT = subcutaneous adipose tissue. NPX = normalized protein expression. RPKM = reads per kilobase per million mapped read. *p<0.05, **p<0.01 and ***p<0.001.*

**CD300LG**

CD300LG displayed increased concentration in serum (+20%, $p<0.001$) together with increased levels in both SkM (+60%, $p<0.001$) and scWAT (+13%, $p=0.01$) mRNA following the 12-week exercise intervention (Figure 5 A-C). Changes in serum CD300LG correlated positively with changes in insulin sensitivity after the intervention (rho=0.59, $p=0.002$; Figure 5 D). In addition, serum CD300LG concentration was lower in overweight than normal weight men (-51%, $p=0.014$) and positively correlated with insulin sensitivity before as well as after the 12-week intervention (pre-trained: $r=0.50$, $p=0.001$, and post-trained: $r=0.43$, $p=0.028$).




***Figure 5. CD300LG.*** *(A) The response from baseline to week 12 in serum CD300LG and CD300LG mRNA in (B) subcutaneous adipose tissue (ScWAT) and (C) skeletal muscle (SkM). (D) Correlation between the change from before to after prolonged exercise in serum CD300LG and insulin sensitivity. (E-H) Pathway enrichment analyses were performed on the top 500 most correlated (and p<0.05) genes in (E) ScWAT or (F) SkM to the change in serum CD300LG levels, or to the change in CD300LG mRNA levels in (G) ScWAT or (H) SkM. Only the top 10 pathways with Q<0.05 are presented. *p<0.05, **p<0.01 and ***p<0.001.*

To investigate the potential effect of serum CD300LG on SkM and ScWAT, we performed an overrepresentation analysis on the top 500 mRNAs that were positively correlated ($p<0.05$) with serum CD300LG levels in each tissue (Figure 5 E-H). Pathway analyses revealed that the change in serum CD300LG concentrations correlated with changes in expression of genes involved in oxidative phosphorylation, G2M check point and hypoxia both in ScWAT and SkM (Figure 5 E-F). In ScWAT, serum CD300LG levels also showed the strongest enrichment with angiogenesis pathways (Figure 5 E). In ScWAT, the change in ScWAT *CD300LG* mRNA levels correlated positively with the change in ScWAT mRNA of genes related to angiogenesis/vasculature development (Figure 5 G). Similar correlations between *CD300LG* mRNA and angiogenesis genes were observed in SkM as well (Figure 5 H). For example, 60% of the mRNAs in the angiogenesis pathway correlated with *CD300LG* (Figure 5 H). However, serum CD300LG levels were also correlated positively with pathways related to fatty acid metabolism in both ScWAT (Figure 5 E) and SkM (Figure 5 H).

To explore tissue specific expression of CD300LG, we utilized data from a publicly available human tissue panel [42]. CD300LG is highly expressed in adipose tissue compared to other tissues (Supplementary Figure 2 A) supporting our observation that ScWAT expression was substantially higher than in SkM (Figure 5 B-C). To further investigate which cells in ScWAT that express CD300LG, we utilized data from a single cell mRNA sequencing atlas of human ScWAT (https://singlecell.broadinstitute.org/single_cell) generated by Emont *et al.* [43]. *CD300LG* mRNA in ScWAT was primarily expressed in venular endothelial cells, but not adipocytes or other cell types present in ScWAT (Supplementary Figure 2 B-E).

We next explored whether CD300LG mediates tissue-tissue cross-talk using data from the GD-CAT (Genetically-Derived Correlations Across Tissues) database [44 45], which is a tool for analyzing human gene expression correlations in and across multiple tissues. In men, ScWAT *CD300LG* correlated strongly with ScWAT, SkM and aortic gene expression (Supplementary Figure 3). Consistent with our observations in the MyoGlu exercise intervention study, the top network of gene expression in ScWAT related to ScWAT *CD300LG* mRNA was angiogenesis (Supplementary Figure 3 A). Like ScWAT, SkM *CD300LG* also correlated strongly with ScWAT, SkM and aortic gene expression (Supplementary Figure 3 B). The proteasome

276 complex was the top network of gene expression related to SkM *CD300LG* mRNA
277 Supplementary Figure 3 B). In contrast, running the same analyses in women did not reveal
278 associations between *CD300LG* and angiogenesis (Supplementary Figure 4 A-B).
279
280 We then evaluated serum CD300LG levels in up to 47,747 samples in the UK biobank (see
281 Methods). Descriptive statistics of the UK biobank cohort are presented in Supplementary
282 Table 5. Serum CD300LG levels were positively associated with several measures of physical
283 activity (all metabolic equivalent tasks, results from the international physical activity
284 questionnaire and meeting the recommended amount of weekly physical activity or not;
285 Table 1). Interestingly, serum CD300LG levels were most strongly related to vigorous activity
286 (Table 1). Furthermore, the associations between serum CD300LG and physical activity were
287 significantly stronger in men than in women (Table 1). Serum CD300LG levels were also
288 positively associated with fat mass and fat free mass, and negatively associated with
289 glucometabolic traits including serum glucose levels, Hb1Ac and the risk of having type 2
290 diabetes (Table 1). These associations were independent of body mass index (BMI).
291

**Table 1.** Multiple regression analyses between serum CD300LG, and measures of physical activity and glucometabolic traits in the UK biobank.

| | Women | | | Men | | | Interaction | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Beta-estimate | SE | P | Beta-estimate | SE | P | Beta-estimate | SE | P | Description | No. of women | No. of men |
| **NPX ~ physical activity** | | | | | | | | | | | | |
| MET per week all activity | 1,0E-06 | 1,2E-06 | 0,384 | 4,5E-06 | 9,9E-07 | <0.001 | 4,3E-06 | 1,5E-06 | 0,005 | MET minutes per week | 22527 | 20726 |
| MET minutes walking | -6,0E-07 | 2,6E-06 | 0,818 | -1,8E-06 | 2,6E-06 | 0,478 | 1,7E-07 | 3,7E-06 | 0,962 | MET minutes per week | 22527 | 20726 |
| MET minutes moderate activity | -2,5E-06 | 2,4E-06 | 0,294 | 1,9E-07 | 2,3E-06 | 0,932 | 1,9E-06 | 3,3E-06 | 0,554 | MET minutes per week | 22527 | 20726 |
| MET minutes vigorous activity | 1,0E-05 | 2,8E-06 | <0.001 | 2,2E-05 | 2,1E-06 | <2e-16 | 1,5E-05 | 3,5E-06 | <0.001 | MET minutes per week | 22527 | 20726 |
| Sedentary overall average | 0,077 | 0,053 | 0,147 | 0,042 | 0,054 | 0,441 | -0,100 | 0,075 | 0,185 | Proportion sedentary activity. | 7430 | 5825 |
| Light overall average | -0,119 | 0,062 | 0,053 | -0,420 | 0,071 | <0.001 | -0,232 | 0,094 | 0,013 | Proportion light activity. | 7430 | 5825 |
| Moderate/vigorous overall average | 0,633 | 0,171 | <0.001 | 1,357 | 0,194 | <0.001 | 1,043 | 0,254 | <0.001 | Proportion moderate/vigorous activity. | 7430 | 5825 |
| IPAQ activity group | 9,6E-03 | 3,8E-03 | 0,012 | 3,1E-02 | 3,8E-03 | <0.001 | 2,6E-02 | 5,4E-03 | <0.001 | IPAQ category | 22527 | 20726 |
| Summed days activity | 1,9E-03 | 5,9E-04 | <0.001 | 3,8E-03 | 5,7E-04 | <0.001 | 2,7E-03 | 8,1E-04 | <0.001 | Days performing walking, moderate and vigorous activity | 23199 | 21138 |
| Summed minutes activity | -1,8E-05 | 3,0E-05 | 0,550 | 6,4E-05 | 2,7E-05 | 0,017 | 9,9E-05 | 4,0E-05 | 0,013 | Mins performing walking, moderate and vigorous activity | 22527 | 20726 |
| Moderate/vigorous recommendation1 | 7,5E-03 | 5,6E-03 | 0,186 | 4,8E-02 | 5,8E-03 | < 2e-16 | 4,6E-02 | 8,0E-03 | <0.001 | Yes/No | 22527 | 20726 |
| Moderate/vigorous walking recommendation1 | -1,3E-05 | 7,2E-03 | 0,999 | 4,0E-02 | 7,4E-03 | <0.001 | 4,6E-02 | 1,0E-02 | <0.001 | Yes/No | 22521 | 20723 |
| **Trait ~ NPX** | | | | | | | | | | | 28108 | 23841 |
| Body fat percentage impedance | -0,137 | 0,051 | 0,007 | -0,552 | 0,052 | <0.001 | -0,375 | 0,073 | <0.001 | Body fat percentage | 28099 | 23802 |
| Whole body fat mass impedance | 0,345 | 0,049 | <0.001 | 0,023 | 0,051 | 0,656 | -0,209 | 0,071 | 0,003 | Fat mass (kg) | 28108 | 23866 |
| Whole body fat free mass impedance | 0,450 | 0,050 | <0.001 | 1,045 | 0,090 | <0.001 | 0,622 | 0,101 | <0.001 | Fat free mass (kg) | 28107 | 23870 |
| Body mass index | - | - | - | - | - | - | - | - | - | kg/m2 | 24810 | 21509 |
| Glucose | -0,066 | 0,016 | <0.001 | -0,041 | 0,022 | 0,062 | 0,033 | 0,026 | 0,202 | mmol/L | 27271 | 23294 |
| HbA1c | -0,898 | 0,078 | <0.001 | -0,911 | 0,107 | <0.001 | -0,010 | 0,130 | 0,936 | mmol/mol | 27323 | 23292 |
| Triglycerides | -0,399 | 0,011 | <0.001 | -0,413 | 0,017 | <0.001 | -0,058 | 0,020 | 0,004 | mmol/L | 28387 | 24332 |
| Type 2 diabetes | -0,012 | 0,002 | <0.001 | -0,018 | 0,004 | <0.001 | 0,000 | 0,004 | 0,982 | Yes/No. | 24802 | 21483 |
| TyG | -2,189 | 0,074 | <0.001 | -2,228 | 0,120 | <0.001 | -0,203 | 0,136 | 0,138 | mmol/L x mmol/L | 22527 | 23841 |

MET = metabolic equivalent of task. NPX = Normalized protein expression. SE = standard error. IPAQ = International physical activity questionnaire. TyG = triglycerid glucose index on insulin resistance.
Model 1 (NPX ~ physical activity) was a linear regression model of NPX values as a function of a measure of physical activity.
Model 2 (Trait ~ NPX) the measures of body composition and glucometabolic traits were the outcomes and NPX values were set as the exposure.
Models 1 and 2 were adjusted for age, batch, study centre, storage time and BMI.
[1]Indicates whether a person met the 2017 UK Physical activity guidelines of 150 minutes of moderate activity per week or 75 minutes of vigorous activity.

## GWAS of serum CD300LG levels

GWAS analyses of CD300LG levels detected 43 independent genome-wide significant genetic associations across the genome (Supplementary Figure 5). The genomic inflation factor ($\lambda$=1.0966) and LD score intercept (1.039) were consistent with our GWAS being well controlled for population stratification and other possible biases (Supplementary Figure 6). The most significant SNPs lay along chromosome 17 with these SNPs mapping to the genomic region encoding the *CD300LG* gene (Supplementary Figure 5). Follow-up analyses revealed three significant, independent *cis*-pQTLs associated with the protein CD300LG (Supplementary Table 6) and a number of *trans*-pQTLs (Supplementary Table 7).

### *Mendelian randomization (MR) analysis*

The independent genome-wide significant SNPs from the CD300LG GWAS were used for two-sample MR (see Methods for details), where 39 SNPs were also available in the outcome GWAS [46]. We first performed Inverse Variance Weighted (IVW) MR analysis to test the causal relationship between CD300LG and fasting glucose, 2-hour post oral glucose tolerance test (OGTT) glucose levels and HbA1c using only *cis*-SNPs (Supplementary Table 8) and all SNPs (Supplementary Table 9). The *cis* IVW MR analysis showed some evidence for a negative causal effect of CD300LG on fasting insulin (p=0.01), but due to only three SNPs in these analyses, we could not perform additional sensitivity analyses (except for tests of heterogeneity in estimates of the causal effect across SNPs) and could not determine whether the absence of strong evidence for a causal effect on the glycaemic parameters was genuine or whether our analyses just lacked power. Although some of the analyses involving all the genome-wide significant SNPs indicated a potential causal link between increased serum CD300LG concentration and these outcomes (Supplementary Table 9) the analysis showed significant heterogeneity. We did not detect strong evidence of directional pleiotropy (significant MR Egger intercept, Supplementary Table 9). The heterogeneity in the analysis is possibly due to the fact that many of the SNPs found in the GWAS of CD300LG are associated with related phenotypes which could exert pleiotropic effects on diabetes related outcomes, and so the results should be interpreted with care (Supplementary Table 10). Due to the heterogeneity in our results we therefore performed MR PRESSO to account for outliers. The MR PRESSO analysis showed a significant negative effect of CD300LG on all outcomes (Table 2).

**Table 2.** Mendelian randomization of serum CD300LG levels and glucose outcomes using MR PRESSO.

| Outcome | MR analysis | Number of outliers | Effect | SD | *p*-value |
|---|---|---|---|---|---|
| 2-hour post OGTT glucose (mmol/L) | Raw | | -0.3722 | 0.0998 | $6.2x10^{-4}$ |
| 2-hour post OGTT glucose (mmol/L) | Outlier-corrected | 2 | -0.3049 | 0.0855 | $1.04x10^{-2}$ |
| Fasting glucose (mmol/L) | Raw | | -0.0307 | 0.0358 | 0.3963 |
| Fasting glucose (mmol/L) | Outlier-corrected | 2 | -0.0556 | 0.0133 | $1.73x10^{-4}$ |
| Fasting insulin (pmol/L) | Raw | | -0.0870 | 0.0558 | 0.1271 |
| Fasting insulin (pmol/L) | Outlier-corrected | 10 | -0.0534 | 0.0252 | 0.0432 |
| HbA1c (%) | Raw | | -0.0485 | 0.0155 | $3.28x10^{-3}$ |
| HbA1c (%) | Outlier-corrected | 3 | -0.0560 | 0.0155 | $1.04x10^{-4}$ |

For detailed results see Supplementary Table 8 and 9. Fasting glucose adjusted for BMI n=200622, 2-hour post oral glucose tolerance test (OGTT) glucose adjusted for BMI n=63396, fasting insulin adjusted for BMI n=151013, and HbA1c n=146806.

*Mouse models*

To functionally validate association of CD300LG with metabolic homeostasis, we leveraged phenotypic data for exercising mice and for *Cd300lg* deficient (*Cd300lg*$^{-/-}$) mice that both were publicly available through the MoTrPAC [47] study and the international mouse phenotyping consortium (PhenoMouse) [48].

There is a 51% homology between human *CD300LG* and mouse *Cd300lg* [49], and also in mice, Cd300lg is predominantly expressed in adipose tissue endothelial cells [43].

In MoTrPAC [47], Cd300lg levels in scWAT from n=12-15 male and female mice were increased after exercise for 8 weeks (~30% in both female (p=0.03) and male (p=0.01) mice) (Supplementary Figure 7 A-C). Based on data from n=3050 mice from PhenoMouse male, but not female, mutants for the *Cd300lg*$^{tm1a(KOMP)Wtsi}$ allele displayed impaired glucose tolerance (Supplementary Figure 7 D), but no change in fasting glucose and insulin (Supplementary Figure 7 E-F). Mutant male, but not female, mice also displayed increased lean mass (Supplementary Figure 7 G) and less fat mass (Supplementary Figure 7 H). Detailed PhenoMouse results are presented in Supplementary Table 11.

## Discussion

In the present study, we characterized the effects of strength and endurance exercise on the serum proteome of sedentary normal weight and overweight men. We identified significant changes in 283 serum proteins related to many signaling pathways after the 12-week intervention. Some of these proteins were related to the mitochondria, muscle differentiation and exercise capacity. Among known secretory proteins, 19.7% and 12.1% displayed corresponding mRNA changes in SkM and ScWAT, respectively. Although some proteins may be myokines, others may be adipokines or other types of exerkines. A multi-tissue responding protein was CD300LG, which also correlated positively to insulin sensitivity. CD300LG was particularly interesting because we could replicate the finding in an external cohort, find evidence of a causal link to glucose homeostasis, and perform functionally validation in mice models. Furthermore, the association between CD300LG, physical activity and glycemic traits might display sex dimorphic relationships.

One of the protein signatures observed in response to exercise was based on strong associations with markers of liver fat content in overweight men. This was related to SLC22A1, which regulates the hepatic glucose-fatty acid cycle affecting gluconeogenesis and lipid metabolism [50], and may influence liver fat accumulation [51]. This signature also shared many common proteins with a known serum NAFLD proteomic signature [38]. However, we did not detect overlaps between proteins in this signature and specific gene expression patterns of liver cells (e.g. hepatocytes, immune cells etc.) [39]. This observation suggests that the proteins detected do not relate to liver protein synthesis per se, but may accumulate in serum due to being released in the blood stream as a result of impaired liver protein catabolism or cell damage as a consequence of overweight/obesity. Notably, this protein signature in overweight men normalized after 12 weeks of exercise and resembled the signature observed in normal weight men. These data suggest prolonged exercise leads to improvements of liver function in overweight men.

Several proteins responding to prolonged exercise had a known signal sequence. These secretory proteins are of particular interest because they could mediate inter-tissue adaptations to exercise. For example, COL1A1 was substantially increased in serum and its corresponding mRNA level was increased in SkM. However, COL1A1 is a collagen peptide

391 that is related to muscle damage, turn-over and extracellular matrix remodeling in response
392 to exercise [52] and may mostly reflect muscle restructuring and not represent signaling effects
393 to distant tissues. The large overlap between serum proteins and SkM mRNA most likely
394 suggests a similar phenomenon, where tissue restructuring following exercise is reflected in
395 blood. However, there are probably also several myokines with distant signaling effects
396 among the identified proteins. CCL3 was reduced in serum in parallel with a reduction in its
397 mRNA level in ScWAT. CCL3 is a monocyte chemoattractant protein that may be related to
398 immune cell infiltration in adipose tissue [53]. Hence, this may reflect a positive effect of
399 prolonged exercise on adipose tissue inflammation, which is in line with our previous results
400 showing normalization of adipose tissue inflammation following prolonged exercise [10].
401
402 A particularly interesting protein was CD300LG, which responded to prolonged exercise in
403 serum, and, judged by its mRNA levels, in SkM and ScWAT. Serum CD300LG levels were
404 lower in overweight compared to normal weight men. Furthermore, the exercise-induced
405 response in CD300LG correlated positively to improvements in insulin sensitivity, and there
406 was also a significant correlation between serum CD300LG and insulin sensitivity both
407 before and after the intervention. We therefore analyzed CD300LG in an external data set,
408 the UK Biobank, and again we observed positive associations between especially vigorous
409 exercise and serum CD300LG. Moreover, serum CD300LG levels were negatively associated
410 with glucose levels and type 2 diabetes in the UK Biobank, and these associations might be
411 causal based on MR analysis. These findings were functionally corroborated by the
412 alterations in glucose tolerance and parameters related to insulin sensitivity observed in
413 *Cd300lg*$^{-/-}$ mice. Thus, CD300LG may represent an exerkine with a causal link to glucose
414 homeostasis. However, whether CD300LG can mediate tissue-tissue crosstalk is unknown.
415 CD300LG is a cell surface protein with a transmembrane domain, but is also a predicted
416 secretory protein [54]. Whether the protein is released from the cell surface in a regulated
417 manner to mediate cross-tissue signaling needs further investigation. Furthermore, the
418 exact link between CD300LG and glucose metabolism is not clear, but possibly related to the
419 fact that CD300LG is expressed in endothelial cells [55], linked to blood pressure [56],
420 lymphocyte binding [57], blood triacylglycerol levels [58,59] and molecular traffic across the
421 capillary endothelium [60]. Both MyoGlu and GD-CAT data also suggested that CD300LG may
422 be related to angiogenesis in ScWAT [61] and SkM [61,62], at least in men. Hence, we speculate

423 that the link between CD300LG and glucose metabolism is related to improved tissue
424 capillarization/vascular function following prolonged exercise. Furthermore, since vigorous
425 exercise leads to angiogenesis in ScWAT and SkM [61], serum CD300LG may be a maker of
426 exercise intensity.
427
428 *Strengths and limitations*
429 Although MyoGlu included only 26 sedentary men, they were extensively phenotyped with
430 euglycemic hyperinsulinemic clamp, fitness tests, whole body imaging (MRI/MRS) and
431 mRNA sequencing of ScWAT and SkM. We also supplied our study with data from 47747
432 persons in the UK biobank to enhance the validity and generalization of the results.
433 Furthermore, to assess sex differences we stratified analyses for men and women in the UK
434 Biobank, in external data bases (GD-CAT[45]) and analyzed data from both male and female
435 mice. Since correlations with the clamp data only imply a role for a protein with regard to
436 glucose homeostasis, so we also tested associations with related glucometabolic traits in the
437 UK Biobank and tested these associations for causality using MR. We also included data from
438 exercised mice, and mutant mice to further strengthen the results. Our serum proteome
439 study assessed 3072 proteins, and therefore we do not cover the complete human
440 proteome. However, the Olink platform is based on dual recognition of correctly matched
441 DNA-labeled antibodies, and DNA sequence-specific protein-to-DNA conversion to generate
442 a signal. This is a highly scalable method with an exceptional specificity
443 (https://olink.com/application/pea/). Previous exercise-proteomic studies has looked at
444 ~600 proteins in overweight men after endurance exercise [25], and three papers were
445 published from the HERITAGE study analyzing ~5000 proteins in response to endurance
446 exercise [26-28]. However, our study is the first and largest exercise study using PEA in both
447 overweight and normal weight men, and also including strength exercise.
448
449 However, CD300LG's role related to angiogenesis is only suggested through association
450 analyses in our data, necessitating follow-up studies to confirm any causal role of CD300LG
451 in angiogenesis. Although the open-source cd300lgtm1a(KOMP)Wtsi mice provided
452 interesting indications, a future study should directly phenotype mice with alterations in the
453 CD300LG gene, and measure the effects on circulating CD300LG levels and potential
454 regulatory mechanisms related to angiogenesis and glucose tolerance. Furthermore, it is

also unknown if circulating CD300LG is full-length or a cleaved fragment, and the mechanisms for CD300LG secretion should be further studied *in vitro*. Finally, future experiments should also identify the epitope for O-link binding, and confirm its specificity using targeted mass spectrometry or antibody-based validations.

*Conclusion*

Our study provided a detailed analysis of serum proteins responding to three months of strength and endurance exercise in both normal weight and overweight men. Our results identified a novel NAFLD-related serum protein signature in overweight men that was normalized after prolonged exercise. We also identified hundreds of tissue-specific and multi-tissue serum markers of e.g., mitochondrial function, muscle differentiation, exercise capacity and insulin sensitivity. Our results were enriched for secretory proteins (exerkines), such as CD300LG, which may be a marker of exercise intensity especially in men, and may also have causal roles in improved glucose homeostasis after physical activity.

## Methods

The MyoGlu study was conducted as a controlled clinical trial (clinicaltrials.gov: NCT01803568) and was carried out in adherence to the principles of the Declaration of Helsinki. The study received ethical approval from the National Regional Committee for Medical and Health Research Ethics North in Tromsø, Norway, with the reference number 2011/882. All participants provided written informed consent before undergoing any procedures related to the study. The UK biobank has ethical approval from the North West Multi-Centre Research Ethics Committee (MREC), which covers the UK, and all participants provided written informed consent. This particular project from the UK biobank received ethical approval from the Institutional Human Research Ethics committee, University of Queensland (approval number 2019002705).

*Participants*

The MyoGlu study enrolled men aged 40 to 65 years who were healthy but sedentary (having engaged in fewer than one exercise session per week in the previous year) [29,63]. These participants were divided into two groups based on their BMI and glucose tolerance: overweight (with an average BMI of 29.5 ± 2.3 kg/m$^2$) and normal weight controls (with an

487 average BMI of 23.6 ± 2.0 kg/m$^2$). The overweight men had reduced glucose tolerance
488 and/or insulin sensitivity (Supplementary Table 1). Both groups, consisting of 13 individuals
489 each, underwent a 12-week regimen of combined strength and endurance training.
490
491 *Exercise protocols*
492 This 12-week training intervention included two weekly sessions of 60 minutes each for
493 endurance cycling and two sessions of 60 minutes each for whole-body strength training.
494 Prior to and after the 12-week exercise intervention, a 45-minute bicycle test at 70% of their
495 maximum oxygen uptake ($VO_2$max) was conducted. Serum, muscle (*m. vastus lateralis*) and
496 subcutaneous white adipose tissue biopsies were taken before, and 48 hours after the last
497 exercise session of the 12-week intervention period [29,63].
498
499 *Clinical data*
500 The euglycaemic hyperinsulinemic clamp was performed after an overnight fast [29,63]. A fixed
501 dose of insulin 40 mU/m$^2$·min$^{-1}$ was infused, and glucose (200 mg/mL) was infused to
502 maintain euglycaemia (5.0 mmol/L) for 150 min. Insulin sensitivity is reported as glucose
503 infusion rate (GIR) during the last 30 min relative to body weight. Whole blood glucose
504 concentration was measured using a glucose oxidase method (YSI 2300, Yellow Springs, OH)
505 and plasma glucose concentration was calculated as whole blood glucose x 1.119. Magnetic
506 resonance imaging/spectroscopy (MRI/MRS) methods were used to quantify fat and lean
507 mass. The ankle-to-neck MRI protocol included a 3D DIXON acquisition providing water and
508 lipid quantification, data were then analysed using the nordicICE software package
509 (NordicNeuroLab, Bergen, Norway), and the jMRUI workflow. $VO_2$max tests were performed
510 after standardized warm-up at a workload similar to the final load of an incremental test in
511 which the relationship between workload (watt) and oxygen uptake was established.
512 Participants cycled for one min followed by a 15 watt increased workload every 30 s until
513 exhaustion. Test success was based on $O_2$ consumption increased <0.5 mL·kg$^{-1}$·min$^{-1}$ over a
514 30 watt increase in workload, respiratory exchange ratio values >1.10, and blood
515 lactate >7.0 mmol/L. We obtained scWAT, SkM biopsies and blood samples as described
516 previously [29]. Biopsies were obtained from the periumbilical subcutaneous tissue and from
517 *m. vastus lateralis*. After sterilization, a lidocaine based local anaesthetic was injected in the
518 skin and sub cutis prior to both SkM and scWAT biopsies. Biopsies were dissected on a cold

519 aluminium plate to remove blood etc. before freezing. For standard serum parameters,
520 measurement were either conducted using standard in-house methods or outsourced to a
521 commercial laboratory (Fürst Laboratories, Oslo, Norway).
522
523 *The Olink proteomics explorer 3072 platform*
524 We utilized antibody-based technology (Olink Proteomics AB, Uppsala, Sweden) to conduct
525 profiling of serum samples through the Olink Explore 3072 panel. This PEA technique
526 involves using pairs of DNA oligonucleotide-labeled antibodies to bind to the proteins of
527 interest. When two matching antibodies attach to a target protein, the linked
528 oligonucleotides hybridize and are extended by DNA polymerase, forming a unique DNA
529 "barcode". This barcode is then read using next-generation sequencing. The specificity and
530 sensitivity of the PEA technology are notably high because only accurately matched DNA
531 pairs generated detectable and measurable signals. To refine the dataset, proteins that were
532 not detected or were duplicated were removed, resulting in an analysis of 2886 proteins.
533 Only a single assay was conducted, eliminating inter-assay variability. Data are presented as
534 normalized protein expression (NPX) units, which are logarithmically scaled using a $\log_2$
535 transformation.
536
537 *Proteomics validations*
538 Duplicate measurements of IL6 and leptin in plasma were conducted using ELISA kits (Leptin;
539 Camarillo, CA and IL6; R&D Systems, Minneapolis, MN) following the manufacturer's
540 instructions. The correlations between PEA or enzyme linked immunosorbent (ELISA) assays
541 were r=0.94 ($p=1.4x10^{-11}$), and r=0.92 ($p=2.2x10^{-11}$) for IL6 and leptin, respectively
542 (Supplementary Figure 1).
543
544 *mRNA sequencing*
545 Biopsies were frozen in liquid nitrogen, crushed to powder by a pestle in a liquid nitrogen-
546 cooled mortar, transferred into 1 mL QIAzol Lysis Reagent (Qiagen, Hilden, Germany), and
547 homogenized using TissueRuptor (Qiagen) at full speed for 15 sec, twice [29,63]. Total RNA was
548 isolated from the homogenate using miRNeasy Mini Kit (Qiagen). RNA integrity and
549 concentration were determined using Agilent RNA 6000 Nano Chips on a Bioanalyzer 2100
550 (Agilent Technologies Inc., Santa Clara, CA). RNA was converted to cDNA using High-Capacity

cDNA Reverse Transcription Kit (Applied Biosystems, Foster, CA). The cDNA reaction mixture was diluted in water and cDNA equivalent of 25 ng RNA used for each sample. All muscle and scWAT samples were deep-sequenced using the Illumina HiSeq 2000 system with multiplex at the Norwegian Sequencing Centre, University of Oslo. Illumina HiSeq RTA (real-time analysis) v1.17.21.3 was used. Reads passing Illumina's recommended parameters were demultiplexed using CASAVA v1.8.2. For prealignment quality checks, we used the software FastQC v0.10.1. The mean library size was ~44 millions unstranded 51 bp single-ended reads for muscle tissue and ~52 millions for scWAT with no differences between groups or time points. No batch effects were present. cDNA sequenced reads alignment was done using Tophat v2.0.8, Samtools v0.1.18, and Bowtie v2.1.0 with default settings against the UCSC hg19 annotated transcriptome and genome dated 14$^{th}$ of May 2013. Post-alignment quality controls were performed using the Integrative Genome Viewer v2.3 and BED tools v2.19.1. Reads were counted using the intersection strict mode in HTSeq v0.6.1.

*Statistics and bioinformatics*

Olink data were analyzed using the 'AnalyzeOlink' R package for pre-processing, testing using mixed linear regression and annotation. Pathway and gene ontology overrepresentation analyses were performed using MSigDB data sets (Hallmark pathways and biological processes). mRNA sequencing data were normalized as reads per kilobase per million mapped read (RPKM) and analyzed using mixed linear regression from the 'lme4' R package. Normality was determined by quantile-quantile plots. P-values were corrected using the Benjamini-Hochberg approach set at a false discovery rate (FDR) of 5%. For univariate correlations, Pearsons' or Spearmans' method were applied as appropriate. Principal component analysis was performed using the 'prcomp' R package. Key driver analysis was performed using the 'Mergeomics' R package. Mediation analysis was performed using the 'Mediation' R package with 1000 bootstraps and the *set.seed* function to ensure reproducibility.

*UK Biobank*

The UK biobank is a large prospective population-based cohort containing ~500,000 individuals (~273,000 women), with a variety of phenotypic and genome-wide genetic data available [64]. The UK biobank has ethical approval from the North West Multi-Centre

583 Research Ethics Committee (MREC), which covers the UK, and all participants provided
584 written informed consent.
585
586 We utilized imputed genetic data from the October 2019 (version 3) release of the UK
587 biobank for our analyses (Application ID: 53641). In addition to the quality control metrics
588 performed centrally by the UK biobank[65], we defined a subset of unrelated "white
589 European" individuals. We excluded those with putative sex chromosome aneuploidy, high
590 heterozygosity or missing rate, or a mismatch between submitted and inferred sex as
591 identified by the UK biobank (total N = 1932). We excluded individuals who we did not
592 identify as ancestrally European using K-means clustering applied to the first four genetic
593 principal components generated from the 1000 Genomes Project [66]. We also excluded
594 individuals who had withdrawn their consent to participate in the study as of February 2021.
595
596 The Olink proteomics explorer 1536 platform
597 All analysis were done using the UK Biobank Olink data containing a total of 58699 samples
598 and 54309 individuals, after excluding individuals as mentioned above we had 47747
599 samples with measured serum CD300LG levels. Data was generated according to Olink's
600 standard procedures.
601
602 Observational analyses
603 For the physical activity measurements we investigated if the degree of physical activity was
604 associated with serum levels of protein (serum levels of protein regressed on physical
605 activity), alternatively for the metabolic measurements we investigated if the protein
606 expression affected the metabolic measurements (trait regressed on serum levels of
607 protein), for both we used a linear regression model. We performed analyses stratified by
608 sex and adjusting for age, protein batch, UK Biobank assessment centre, the time the sample
609 was stored and BMI. All analyses were performed in R version 3.4.3.
610
611 Genome-wide association analysis
612 A GWAS of serum CD300LG levels ($log_2$ transformed) measured in the UK Biobank was
613 performed using BOLT-LMM [67] on individuals of European descent who had proteomic data
614 available (N=45788). We included sex, year of birth, protein and genotyping batch, time

615 from sample collection to processing time (in weeks) and five ancestry informative principal
616 components as covariates in the analysis.
617
618 Post GWAS quality control included the removal of SNPs with MAF ≤0.05 and info score ≤0.4
619 ($n_{SNPs}$=6,945,819). The previously generated LD reference panel for clumping consisted of a
620 random sample of 47674 unrelated British UK biobank individuals identified using GCTA [68]
621 with identity by state (IBS)<0.025 and identity by descent (IBD) sharing of <0.1. LD score
622 regression analysis [69] was used to investigate whether genomic inflation was likely due to
623 polygenicity or population stratification/cryptic relatedness.
624
625 Prior to gene annotation palindromic SNPs were excluded ($n_{SNPs}$=6,882,889 remaining).
626 Variants were classified as either *cis*- or *trans*-pQTLs based on SNP proximity to the protein-
627 encoding gene (CD300LG) of interest. Variant annotation was performed using ANNOVAR [70],
628 labelling genes +/-500kb from variants. A pQTL was considered a cis-pQTL if the gene
629 annotation in the 1Mb window matched the protein name, all remaining variants were
630 considered trans-pQTLs.
631
632 To extract independent genome-wide significant pQTLs ($p<5\times10^{-8}$) clumping was
633 performed using the PLINK v1.90b3.31 software package [71]; variants with $r^2>0.001$ with the
634 index SNP were removed using a 1 Mb window. Variants which lied within the human major
635 histocompatibility complex (MHC) region were removed, excluding pQTLs on chromosome 6
636 from 26Mb to 34Mb.
637
638 *Mendelian Randomization (MR)*
639 To obtain valid instrumental variables (SNPs) for our analysis we assessed them against the
640 three core assumptions for MR analysis: 1) That the SNPs were robustly associated with the
641 exposure of interest. For that we obtained summary result statistics on genome-wide
642 significant SNPs from our own GWAS. 2) That the SNPs were not associated with any known
643 or unknown confounders. This is not an assumption that can be fully tested, however we
644 used PhenoScanner [72,73] to assess whether any SNPs were associated with known
645 confounders (described below). 3) That the SNPs were not associated with the outcomes
646 through any other path than through the exposure. To test this assumption, we searched

PhenoScanner [72,73] (detailed below) to see if our exposures of interest were associated with other potentially pleiotropic phenotypes.

MR statistical analysis

We used the TwoSampleMR package [74] (https://github.com/MRCIEU/TwoSampleMR) in R version 4.2.2 (https://cran.r-project.org/). The outcome studies were obtained from https://www.magicinvestigators.org/ [46] and were external to the UK biobank. Specificially, we used the outcomes "fasting glucose adjusted for BMI" (mmol/L, n=200622), "2-hour post OGTT glucose adjusted for BMI" (mmol/L, n=63396), "fasting insulin adjusted for BMI" (pmol/L, n=151013) and "HbA1c" (%, n=146806) [46].

We performed a two-sample inverse variance weighted (IVW) analysis to assess the causal effect of CD300LG on metabolic factors (Supplementary Table 8 and 9). To explore potential violations of the core assumptions when using the full set of SNPs, we performed a heterogeneity test using Cochran's Q, and a test for directional pleiotropy was conducted by assessing the degree to which the MR Egger intercept differed from zero [75]. We also performed additional sensitivity analyses using MR Egger regression [75], weighted median [76], simple and weighted mode estimation methods [77]. Effect estimates from the different sensitivity analysis were compared as a way of assessing the robustness of the results. To assess potential heterogeneity in the MR estimates we further performed MR-PRESSO [46,78] to detect (MR-PRESSO global test) and correct for horizontal pleiotropy via outlier removal (MR-PRESSO outlier test).

Investigation of potentially pleiotropic SNPs

SNPs robustly associated with the exposure investigated in the MR analyses (serum CD300LG levels) were checked for other possible associations (PhenoScanner v2 [72,73], http://www.phenoscanner.medschl.cam.ac.uk/) which may contribute to a pleiotropic effect on the metabolic outcomes. Supplementary Table 10 lists the SNPs used in our analysis that many influence related phenotypes. Phenotypes from PhenoScanner were listed if they were associated with the SNPs or nearby variants in high LD ($r^2$=0.8) at p-value level <1 x $10^{-5}$ and could have potential pleiotropic effects in the analysis.

*Data availability*

mRNA sequencing data from MyoGlu can be found at https://exchmdpmg.medsch.ucla.edu/app/ as well as in GEO:GSE227419. Secretory proteins are available in the MetazSecKB data base at http://proteomics.ysu.edu/secretomes/animal/. The human serum proteomic NAFLD signature is available in the study of Govaere *et al* [38]. Expression profiles in human liver cells are available in the Human Liver Cell Atlas [39]. Data obtained from the UK biobank (Olink explore 1536 and measures of physical activity [79] can be found at https://biobank.ndph.ox.ac.uk/ukb/. Glucometabolic outcomes used in MR analyses are available at: https://www.magicinvestigators.org/ [46]. Data from the GD-CAT database [45] is available from: https://pipeline.biochem.uci.edu/gtex/demo2/. Mice exercise data are available at https://motrpac-data.org/ and knock-out data at https://www.mousephenotype.org/. CD300LG expression values from a human tissue panel were obtained from Uhlén *et al.* [42]. The single nuclei mRNA sequencing data from human adipose tissue was plotted in Seurat v. 4 by downloading processed data from the Single Cell Portal [43]. The data can also be explored at: https://singlecell.broadinstitute.org/single_cell/study/SCP1376/a-single-cell-atlas-of-human-and-mouse-white-adipose-tissue). UK Biobank (https://www.ukbiobank.ac.uk/) data are available to researchers upon application to the individual cohorts via their websites. All other data used are publicly available and referenced according in the main text. For additional details and data inquiries, please contact Sindre Lee-Ødegård.

**Acknowledgements**

South-Eastern Norway Regional Health Authority, Simon Fougners fund, Diabetesforbundet, Johan Selmer Kvanes' legat til forskning og bekjempelse av sukkersyke. This research has been conducted using the UK Biobank resource (Reference 53641). DME is funded by an Australian National Health and Medical Research Council Investigator Grant (APP2017942). GHM is the recipient of an Australian Research Council Discovery Early Career Award (Project number: DE220101226) funded by the Australian Government and supported by the Research Council of Norway (Project grant: 325640 & Mobility grant: 287198). JKV is supported by The Medical Student Research Program at the University of Oslo. SL is

supported by the Novo Nordisk Fonden Excellence Emerging Grant in Endocrinology and Metabolism 2023 (NNF23OC0082123).

## Author contributions

Conceptualization: SLØ, CAD, KIB. Methodology: SLØ, GHM, ED, DME. Data Collection: SLØ, FN. Data analysis: SLØ, TO, MH, GHM, ED. Visualization: SLØ, GHM and MH. Writing original draft: SLØ. Writing, review and editing: SLØ, MH, TO, GHM, ED, DME, JKV, HLG, FN, CAD, KIB. Supervision: CAD, KIB. Funding acquisition : SLØ, CAD, KIB. Project administration: KIB.

## Competing interests

The authors declare no conflict of interest.

## References

1. Piercy, K.L., Troiano, R.P., Ballard, R.M., Carlson, S.A., Fulton, J.E., Galuska, D.A., George, S.M., and Olson, R.D. (2018). The Physical Activity Guidelines for Americans. Jama *320*, 2020-2028. 10.1001/jama.2018.14854.
2. Hawley, J.A., and Lessard, S.J. (2008). Exercise training-induced improvements in insulin action. Acta Physiol (Oxf) *192*, 127-135. 10.1111/j.1748-1716.2007.01783.x.
3. Bacchi, E., Negri, C., Zanolin, M.E., Milanese, C., Faccioli, N., Trombetta, M., Zoppini, G., Cevese, A., Bonadonna, R.C., Schena, F., et al. (2012). Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). Diabetes care *35*, 676-682. 10.2337/dc11-1655.
4. Pedersen, B.K., Akerström, T.C., Nielsen, A.R., and Fischer, C.P. (2007). Role of myokines in exercise and metabolism. Journal of applied physiology (Bethesda, Md. : 1985) *103*, 1093-1098. 10.1152/japplphysiol.00080.2007.
5. Chow, L.S., Gerszten, R.E., Taylor, J.M., Pedersen, B.K., van Praag, H., Trappe, S., Febbraio, M.A., Galis, Z.S., Gao, Y., Haus, J.M., et al. (2022). Exerkines in health, resilience and disease. Nat Rev Endocrinol *18*, 273-289. 10.1038/s41574-022-00641-2.
6. Görgens, S.W., Eckardt, K., Jensen, J., Drevon, C.A., and Eckel, J. (2015). Exercise and Regulation of Adipokine and Myokine Production. Progress in molecular biology and translational science *135*, 313-336. 10.1016/bs.pmbts.2015.07.002.
7. Lee-Ødegård, S., Olsen, T., Norheim, F., Drevon, C.A., and Birkeland, K.I. (2022). Potential Mechanisms for How Long-Term Physical Activity May Reduce Insulin Resistance. Metabolites *12*. 10.3390/metabo12030208.
8. Pourteymour, S., Eckardt, K., Holen, T., Langleite, T., Lee, S., Jensen, J., Birkeland, K.I., Drevon, C.A., and Hjorth, M. (2017). Global mRNA sequencing of human skeletal muscle: Search for novel exercise-regulated myokines. Molecular metabolism *6*, 352-365. 10.1016/j.molmet.2017.01.007.

9. Pedersen, B.K., and Febbraio, M.A. (2012). Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol *8*, 457-465. 10.1038/nrendo.2012.49.
10. Lee, S., Norheim, F., Langleite, T.M., Gulseth, H.L., Birkeland, K.I., and Drevon, C.A. (2019). Effects of long-term exercise on plasma adipokine levels and inflammation-related gene expression in subcutaneous adipose tissue in sedentary dysglycaemic, overweight men and sedentary normoglycaemic men of healthy weight. Diabetologia *62*, 1048-1064. 10.1007/s00125-019-4866-5.
11. Bouassida, A., Chamari, K., Zaouali, M., Feki, Y., Zbidi, A., and Tabka, Z. (2010). Review on leptin and adiponectin responses and adaptations to acute and chronic exercise. Br J Sports Med *44*, 620-630. 10.1136/bjsm.2008.046151.
12. Stanford, K.I., Lynes, M.D., Takahashi, H., Baer, L.A., Arts, P.J., May, F.J., Lehnig, A.C., Middelbeek, R.J.W., Richard, J.J., So, K., et al. (2018). 12,13-diHOME: An Exercise-Induced Lipokine that Increases Skeletal Muscle Fatty Acid Uptake. Cell metabolism *27*, 1111-1120.e1113. 10.1016/j.cmet.2018.03.020.
13. Lee, S., Norheim, F., Gulseth, H.L., Langleite, T.M., Kolnes, K.J., Tangen, D.S., Stadheim, H.K., Gilfillan, G.D., Holen, T., Birkeland, K.I., et al. (2017). Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise. Physiological reports *5*. 10.14814/phy2.13183.
14. Kistner, T.M., Pedersen, B.K., and Lieberman, D.E. (2022). Interleukin 6 as an energy allocator in muscle tissue. Nature Metabolism *4*, 170-179. 10.1038/s42255-022-00538-4.
15. Haugen, F., Norheim, F., Lian, H., Wensaas, A.J., Dueland, S., Berg, O., Funderud, A., Skålhegg, B.S., Raastad, T., and Drevon, C.A. (2010). IL-7 is expressed and secreted by human skeletal muscle cells. Am J Physiol Cell Physiol *298*, C807-816. 10.1152/ajpcell.00094.2009.
16. Otaka, N., Shibata, R., Ohashi, K., Uemura, Y., Kambara, T., Enomoto, T., Ogawa, H., Ito, M., Kawanishi, H., Maruyama, S., et al. (2018). Myonectin Is an Exercise-Induced Myokine That Protects the Heart From Ischemia-Reperfusion Injury. Circ Res *123*, 1326-1338. 10.1161/circresaha.118.313777.
17. Hjorth, M., Pourteymour, S., Görgens, S.W., Langleite, T.M., Lee, S., Holen, T., Gulseth, H.L., Birkeland, K.I., Jensen, J., Drevon, C.A., and Norheim, F. (2016). Myostatin in relation to physical activity and dysglycaemia and its effect on energy metabolism in human skeletal muscle cells. Acta Physiol (Oxf) *217*, 45-60. 10.1111/apha.12631.
18. McPherron, A.C., Lawler, A.M., and Lee, S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature *387*, 83-90. 10.1038/387083a0.
19. Rao, R.R., Long, J.Z., White, J.P., Svensson, K.J., Lou, J., Lokurkar, I., Jedrychowski, M.P., Ruas, J.L., Wrann, C.D., Lo, J.C., et al. (2014). Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell *157*, 1279-1291. 10.1016/j.cell.2014.03.065.
20. Kanzleiter, T., Rath, M., Gorgens, S.W., Jensen, J., Tangen, D.S., Kolnes, A.J., Kolnes, K.J., Lee, S., Eckel, J., Schurmann, A., and Eckardt, K. (2014). The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochemical and biophysical research communications *450*, 1089-1094. 10.1016/j.bbrc.2014.06.123.

21. Malin, S.K., del Rincon, J.P., Huang, H., and Kirwan, J.P. (2014). Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity. Medicine and science in sports and exercise *46*, 2085-2090. 10.1249/mss.0000000000000338.
22. Catoire, M., Alex, S., Paraskevopulos, N., Mattijssen, F., Evers-van Gogh, I., Schaart, G., Jeppesen, J., Kneppers, A., Mensink, M., Voshol, P.J., et al. (2014). Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise. Proceedings of the National Academy of Sciences of the United States of America *111*, E1043-1052. 10.1073/pnas.1400889111.
23. Norheim, F., Hjorth, M., Langleite, T.M., Lee, S., Holen, T., Bindesboll, C., Stadheim, H.K., Gulseth, H.L., Birkeland, K.I., Kielland, A., et al. (2014). Regulation of angiopoietin-like protein 4 production during and after exercise. Physiological reports *2*. 10.14814/phy2.12109.
24. Contrepois, K., Wu, S., Moneghetti, K.J., Hornburg, D., Ahadi, S., Tsai, M.S., Metwally, A.A., Wei, E., Lee-McMullen, B., Quijada, J.V., et al. (2020). Molecular Choreography of Acute Exercise. Cell *181*, 1112-1130.e1116. 10.1016/j.cell.2020.04.043.
25. Diaz-Canestro, C., Chen, J., Liu, Y., Han, H., Wang, Y., Honoré, E., Lee, C.H., Lam, K.S.L., Tse, M.A., and Xu, A. (2023). A machine-learning algorithm integrating baseline serum proteomic signatures predicts exercise responsiveness in overweight males with prediabetes. Cell Rep Med *4*, 100944. 10.1016/j.xcrm.2023.100944.
26. Robbins, J.M., Peterson, B., Schranner, D., Tahir, U.A., Rienmüller, T., Deng, S., Keyes, M.J., Katz, D.H., Beltran, P.M.J., Barber, J.L., et al. (2021). Human plasma proteomic profiles indicative of cardiorespiratory fitness. Nat Metab *3*, 786-797. 10.1038/s42255-021-00400-z.
27. Robbins, J.M., Rao, P., Deng, S., Keyes, M.J., Tahir, U.A., Katz, D.H., Beltran, P.M.J., Marchildon, F., Barber, J.L., Peterson, B., et al. (2023). Plasma proteomic changes in response to exercise training are associated with cardiorespiratory fitness adaptations. JCI Insight *8*. 10.1172/jci.insight.165867.
28. Mi, M.Y., Barber, J.L., Rao, P., Farrell, L.A., Sarzynski, M.A., Bouchard, C., Robbins, J.M., and Gerszten, R.E. (2023). Plasma Proteomic Kinetics in Response to Acute Exercise. Mol Cell Proteomics *22*, 100601. 10.1016/j.mcpro.2023.100601.
29. Langleite, T.M., Jensen, J., Norheim, F., Gulseth, H.L., Tangen, D.S., Kolnes, K.J., Heck, A., Storas, T., Grothe, G., Dahl, M.A., et al. (2016). Insulin sensitivity, body composition and adipose depots following 12 w combined endurance and strength training in dysglycemic and normoglycemic sedentary men. Archives of physiology and biochemistry *122*, 167-179. 10.1080/13813455.2016.1202985.
30. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015). UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine *12*, e1001779. 10.1371/journal.pmed.1001779.
31. Hamaguchi, H., Dohi, K., Sakai, T., Taoka, M., Isobe, T., Matsui, T.S., Deguchi, S., Furuichi, Y., Fujii, N.L., and Manabe, Y. (2023). PDGF-B secreted from skeletal muscle enhances myoblast proliferation and myotube maturation via activation of the PDGFR signaling cascade. Biochemical and biophysical research communications *639*, 169-175. https://doi.org/10.1016/j.bbrc.2022.11.085.
32. Lories, R.J., Peeters, J., Szlufcik, K., Hespel, P., and Luyten, F.P. (2009). Deletion of frizzled-related protein reduces voluntary running exercise performance in mice. Osteoarthritis Cartilage *17*, 390-396. 10.1016/j.joca.2008.07.018.

33. Casas-Fraile, L., Cornelis, F.M., Costamagna, D., Rico, A., Duelen, R., Sampaolesi, M.M., López de Munain, A., Lories, R.J., and Sáenz, A. (2020). Frizzled related protein deficiency impairs muscle strength, gait and calpain 3 levels. Orphanet Journal of Rare Diseases *15*, 119. 10.1186/s13023-020-01372-1.
34. López-Bellón, S., Rodríguez-López, S., González-Reyes, J.A., Burón, M.I., de Cabo, R., and Villalba, J.M. (2022). CYB5R3 overexpression preserves skeletal muscle mitochondria and autophagic signaling in aged transgenic mice. Geroscience *44*, 2223-2241. 10.1007/s11357-022-00574-8.
35. Tassi, E., Garman, K.A., Schmidt, M.O., Ma, X., Kabbara, K.W., Uren, A., Tomita, Y., Goetz, R., Mohammadi, M., Wilcox, C.S., et al. (2018). Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Sci Rep *8*, 15973. 10.1038/s41598-018-34238-5.
36. Qian, Q., Hu, F., Yu, W., Leng, D., Li, Y., Shi, H., Deng, D., Ding, K., Liang, C., and Liu, J. (2023). SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1-Dependent Manner. J Am Heart Assoc *12*, e028628. 10.1161/jaha.122.028628.
37. Chen, H.H., Luche, R., Wei, B., and Tonks, N.K. (2004). Characterization of two distinct dual specificity phosphatases encoded in alternative open reading frames of a single gene located on human chromosome 10q22.2. The Journal of biological chemistry *279*, 41404-41413. 10.1074/jbc.M405286200.
38. Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J.M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023). A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nature Metabolism *5*, 572-578. 10.1038/s42255-023-00775-1.
39. Aizarani, N., Saviano, A., Sagar, Mailly, L., Durand, S., Herman, J.S., Pessaux, P., Baumert, T.F., and Grün, D. (2019). A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature *572*, 199-204. 10.1038/s41586-019-1373-2.
40. Montgomery, M.K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., Schittenhelm, R.B., Ryan, A., Townley, S.L., Selth, L.A., et al. (2020). SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Sci Transl Med *12*. 10.1126/scitranslmed.aaz8048.
41. Ghodsian, N., Gagnon, E., Bourgault, J., Gobeil, É., Manikpurage, H.D., Perrot, N., Girard, A., Mitchell, P.L., and Arsenault, B.J. (2021). Blood Levels of the SMOC1 Hepatokine Are Not Causally Linked with Type 2 Diabetes: A Bidirectional Mendelian Randomization Study. Nutrients *13*. 10.3390/nu13124208.
42. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science (New York, N.Y.) *347*, 1260419. 10.1126/science.1260419.
43. Emont, M.P., Jacobs, C., Essene, A.L., Pant, D., Tenen, D., Colleluori, G., Di Vincenzo, A., Jørgensen, A.M., Dashti, H., Stefek, A., et al. (2022). A single-cell atlas of human and mouse white adipose tissue. Nature *603*, 926-933. 10.1038/s41586-022-04518-2.
44. Battle, A., Brown, C.D., Engelhardt, B.E., and Montgomery, S.B. (2017). Genetic effects on gene expression across human tissues. Nature *550*, 204-213. 10.1038/nature24277.

45. Zhou, M., Tamburini, I., Van, C., Molendijk, J., Nguyen, C.M., Chang, I.Y.-Y., Johnson, C., Velez, L.M., Cheon, Y., Yeo, R., et al. (2024). Leveraging inter-individual transcriptional correlation structure to infer discrete signaling mechanisms across metabolic tissues. eLife *12*, RP88863. 10.7554/eLife.88863.
46. Chen, J., Spracklen, C.N., Marenne, G., Varshney, A., Corbin, L.J., Luan, J., Willems, S.M., Wu, Y., Zhang, X., Horikoshi, M., et al. (2021). The trans-ancestral genomic architecture of glycemic traits. Nat Genet *53*, 840-860. 10.1038/s41588-021-00852-9.
47. Sanford, J.A., Nogiec, C.D., Lindholm, M.E., Adkins, J.N., Amar, D., Dasari, S., Drugan, J.K., Fernández, F.M., Radom-Aizik, S., Schenk, S., et al. (2020). Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. Cell *181*, 1464-1474. 10.1016/j.cell.2020.06.004.
48. Dickinson, M.E., Flenniken, A.M., Ji, X., Teboul, L., Wong, M.D., White, J.K., Meehan, T.F., Weninger, W.J., Westerberg, H., Adissu, H., et al. (2016). High-throughput discovery of novel developmental phenotypes. Nature *537*, 508-514. 10.1038/nature19356.
49. Takatsu, H., Hase, K., Ohmae, M., Ohshima, S., Hashimoto, K., Taniura, N., Yamamoto, A., and Ohno, H. (2006). CD300 antigen like family member G: A novel Ig receptor like protein exclusively expressed on capillary endothelium. Biochemical and biophysical research communications *348*, 183-191. https://doi.org/10.1016/j.bbrc.2006.07.047.
50. Liang, X., Yee, S.W., Chien, H.C., Chen, E.C., Luo, Q., Zou, L., Piao, M., Mifune, A., Chen, L., Calvert, M.E., et al. (2018). Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biol *16*, e2002907. 10.1371/journal.pbio.2002907.
51. Chen, L., Shu, Y., Liang, X., Chen, E.C., Yee, S.W., Zur, A.A., Li, S., Xu, L., Keshari, K.R., Lin, M.J., et al. (2014). OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences of the United States of America *111*, 9983-9988. 10.1073/pnas.1314939111.
52. Jacob, Y., Anderton, R.S., Cochrane Wilkie, J.L., Rogalski, B., Laws, S.M., Jones, A., Spiteri, T., Hince, D., and Hart, N.H. (2022). Genetic Variants within NOGGIN, COL1A1, COL5A1, and IGF2 are Associated with Musculoskeletal Injuries in Elite Male Australian Football League Players: A Preliminary Study. Sports Medicine - Open *8*, 126. 10.1186/s40798-022-00522-y.
53. Barry, J.C., Simtchouk, S., Durrer, C., Jung, M.E., and Little, J.P. (2017). Short-Term Exercise Training Alters Leukocyte Chemokine Receptors in Obese Adults. Medicine and science in sports and exercise *49*, 1631-1640. 10.1249/mss.0000000000001261.
54. Meinken, J., Walker, G., Cooper, C.R., and Min, X.J. (2015). MetazSecKB: the human and animal secretome and subcellular proteome knowledgebase. Database (Oxford) *2015*. 10.1093/database/bav077.
55. Umemoto, E., Takeda, A., Jin, S., Luo, Z., Nakahogi, N., Hayasaka, H., Lee, C.M., Tanaka, T., and Miyasaka, M. (2013). Dynamic changes in endothelial cell adhesion molecule nepmucin/CD300LG expression under physiological and pathological conditions. PloS one *8*, e83681. 10.1371/journal.pone.0083681.
56. Støy, J., Grarup, N., Hørlyck, A., Ibsen, L., Rungby, J., Poulsen, P.L., Brandslund, I., Christensen, C., Hansen, T., Pedersen, O., et al. (2014). Blood pressure levels in male carriers of Arg82Cys in CD300LG. PloS one *9*, e109646. 10.1371/journal.pone.0109646.

57. Umemoto, E., Tanaka, T., Kanda, H., Jin, S., Tohya, K., Otani, K., Matsutani, T., Matsumoto, M., Ebisuno, Y., Jang, M.H., et al. (2006). Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. J Exp Med *203*, 1603-1614. 10.1084/jem.20052543.
58. Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., Timonen, S., et al. (2015). The impact of low-frequency and rare variants on lipid levels. Nature Genetics *47*, 589-597. 10.1038/ng.3300.
59. Støy, J., Kampmann, U., Mengel, A., Magnusson, N.E., Jessen, N., Grarup, N., Rungby, J., Stødkilde-Jørgensen, H., Brandslund, I., Christensen, C., et al. (2015). Reduced CD300LG mRNA tissue expression, increased intramyocellular lipid content and impaired glucose metabolism in healthy male carriers of Arg82Cys in CD300LG: a novel genometabolic cross-link between CD300LG and common metabolic phenotypes. BMJ Open Diabetes Res Care *3*, e000095. 10.1136/bmjdrc-2015-000095.
60. Takatsu, H., Hase, K., Ohmae, M., Ohshima, S., Hashimoto, K., Taniura, N., Yamamoto, A., and Ohno, H. (2006). CD300 antigen like family member G: A novel Ig receptor like protein exclusively expressed on capillary endothelium. Biochemical and biophysical research communications *348*, 183-191. 10.1016/j.bbrc.2006.07.047.
61. Van Pelt, D.W., Guth, L.M., and Horowitz, J.F. (2017). Aerobic exercise elevates markers of angiogenesis and macrophage IL-6 gene expression in the subcutaneous adipose tissue of overweight-to-obese adults. Journal of applied physiology *123*, 1150-1159. 10.1152/japplphysiol.00614.2017.
62. Ross, M., Kargl, C.K., Ferguson, R., Gavin, T.P., and Hellsten, Y. (2023). Exercise-induced skeletal muscle angiogenesis: impact of age, sex, angiocrines and cellular mediators. European Journal of Applied Physiology *123*, 1415-1432. 10.1007/s00421-022-05128-6.
63. Lee, S., Gulseth, H.L., Langleite, T.M., Norheim, F., Olsen, T., Refsum, H., Jensen, J., Birkeland, K.I., and Drevon, C.A. (2021). Branched-chain amino acid metabolism, insulin sensitivity and liver fat response to exercise training in sedentary dysglycaemic and normoglycaemic men. Diabetologia *64*, 410-423. 10.1007/s00125-020-05296-0.
64. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med *12*, e1001779. 10.1371/journal.pmed.1001779.
65. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature *562*, 203-209. 10.1038/s41586-018-0579-z.
66. Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., and Abecasis, G.R. (2015). A global reference for human genetic variation. Nature *526*, 68-74. 10.1038/nature15393.
67. Loh, P.-R., Tucker, G., Bulik-Sullivan, B.K., Vilhjálmsson, B.J., Finucane, H.K., Salem, R.M., Chasman, D.I., Ridker, P.M., Neale, B.M., Berger, B., et al. (2015). Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nature Genetics *47*, 284-290. 10.1038/ng.3190.

68. Wu, Y., Burch, K.S., Ganna, A., Pajukanta, P., Pasaniuc, B., and Sankararaman, S. (2022). Fast estimation of genetic correlation for biobank-scale data. The American Journal of Human Genetics *109*, 24-32. https://doi.org/10.1016/j.ajhg.2021.11.015.
69. Lee, J.J., McGue, M., Iacono, W.G., and Chow, C.C. (2018). The accuracy of LD Score regression as an estimator of confounding and genetic correlations in genome-wide association studies. Genet Epidemiol *42*, 783-795. 10.1002/gepi.22161.
70. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res *38*, e164. 10.1093/nar/gkq603.
71. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics *81*, 559-575. 10.1086/519795.
72. Staley, J.R., Blackshaw, J., Kamat, M.A., Ellis, S., Surendran, P., Sun, B.B., Paul, D.S., Freitag, D., Burgess, S., Danesh, J., et al. (2016). PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics (Oxford, England) *32*, 3207-3209. 10.1093/bioinformatics/btw373.
73. Kamat, M.A., Blackshaw, J.A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth, A.S., and Staley, J.R. (2019). PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics (Oxford, England) *35*, 4851-4853. 10.1093/bioinformatics/btz469.
74. Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018). The MR-Base platform supports systematic causal inference across the human phenome. eLife *7*, e34408. 10.7554/eLife.34408.
75. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol *44*, 512-525. 10.1093/ije/dyv080.
76. Bowden, J., Del Greco, M.F., Minelli, C., Davey Smith, G., Sheehan, N.A., and Thompson, J.R. (2016). Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol *45*, 1961-1974. 10.1093/ije/dyw220.
77. Hartwig, F.P., Davey Smith, G., and Bowden, J. (2017). Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol *46*, 1985-1998. 10.1093/ije/dyx102.
78. Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics *50*, 693-698. 10.1038/s41588-018-0099-7.
79. Sophie, C., Josephine, Y.C., Michael, C., Adrian, B., and Michael, I.T. (2016). Cross-sectional study of diet, physical activity, television viewing and sleep duration in 233 110 adults from the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes. BMJ Open *6*, e010038. 10.1136/bmjopen-2015-010038.


MyoGlu
Blood, muscle & fat
Normal weight
or
overweight
12-week strength & endurance exercise
Blood, muscle & fat
Sedentary
Clamp
VO2max
Maximum leg press
Maximum pull down
Maximum chest press
MRI/MRS
Trained
Clamp
VO2max
Maximum leg press
Maximum pull down
Maximum chest press
MRI/MRS


Changed proteins
Exerkines
UK biobank
Mendelian randomization
Mouse exercise model
Mouse knock out model
Casual links
to glucose
metabolism


A
All
Dn
Up
EDAR
SRC
MEGF10
EGF
CD300LG
DUSP13
-lg10(Q)
ΔNPX
B
NW
CD84
CD300LG
EDAR
CD93
SRC
IL6
C
OW
CA14
DUSP13
TREML1
ACY1
MYBPC1
COL1A1
D
Up-regulated
E
Down-regulated
35
12
20
10
30
0
19
21
6
4
13
47
0
66


A
Up-regulated
All
NW
OW
35
12
20
30
10
0
19
B
Down-regulated
All
NW
OW
21
6
4
47
13
0
66
C
supramolecular polymer
supramolecular complex
small molecule metabolic process
small molecule catabolic process
oxidoreductase activity
organic acid metabolic process
organic acid catabolic process
monocarboxylic acid metabolic process
growth factor receptor binding
cellular amino acid catabolic process
-1.5 -1.0 -0.5 0.0
NES
Q
0.015
0.012
0.009
0.006
D
AMBI
ECHS1
TDO2
GGT1
SLC22A1
IGFBP4
GSTA3
DCXR
SERPINF2
E
NAFLD signature
OW trained
460
16 (24%)
50
F
OW baseline
OW trained
NW baseline
Proteins levels Z score
-1
0
1
G
Liver fat (AU)
Rho=0.57**
PC1
H
Liver fat (AU)
PC1
I
M (mg/kg/min)
Rho=-0.54**
PC1
J
M (mg/kg/min)
PC1
K
Liver fat
B=-0.26*
M
Liver fat
B=0.72**
PC1
Liver fat
B=-0.10
M
PC1
B=-0.22*
Mediated effect: 36.9%***
L
Baseline
Trained
Leu
Isoleu
Valine
Tyr
Phe
Tryp
Kyh
Gly
aHB
bHB
AcAc
IL−6
TNFa
ASAT
ALAT
TG
HDL
LDL
Pancreatic fat
Spearman's rho
-0.6
0.9


A
SkM
log2(fold-change)
COL1A1
THY1
CD300LG
Up
Down
RGMA
CA14
CHAD
B
12w
B
ScWAT
SMOC1
CHAD
CD300LG
LDLR
ACP5
CCL3
C
SkM
ScWAT
Blood
ACP5
ANGPTL2
ARSB
CA14
CA6
CCL3
CCL7
CD300LG
CD40
CDCP1
CDHR2
CDNF
CHAD
CNTN1
COL1A1
CRTAC1
CXCL14
DAG1
DPP4
ENPP5
FCGR3B
FGF16
FGFBP3
FRZB
GP1BB
GUSB
IFNAR1
IGSF21
IL1R1
LDLR
LEP
PDGFB
PGA4
PTPRK
RALY
RARRES2
RGMA
RNASE10
ROBO4
RSPO1
S100A12
SCGB1A1
SCPEP1
SERPINF2
SIAE
SMOC1
SMOC2
SPINK6
SPINK8
SSC4D
SSC5D
SUSD1
THY1
TNFRSF14
TREM2
TYRP1
All participants
CFP
EPGN
IL6
IL7
TTR
NW
AMBP
APOH
COMP
CRH
DMP1
IGFBP4
IL15
INHBC
MFAP4
PINLYP
PRSS27
SORD
OW
log2(FC)
1.0
0.5
0.0
-0.5
-1.0
D
COL1A1 log2(RPKM)
E
COL1A1 (NPX)
F
CCL3 log2(RPKM)
G
CCL3 (NPX)
H
Up-regulated
Blood
SkM
ScWAT
18
7
10
2
1
0
0
I
Down-regulated
Blood
SkM
ScWAT
22
0
5
6
0
0
2


A
Blood
CD300LG (NPX)
***
B
12w
B
ScWAT
CD300LG log2(RPKM)
*
B
12w
C
SkM
CD300LG log2(RPKM)
***
B
12w
D
Rho=0.59**
ΔM (mg/kg/min)
ΔCD300LG (NPX)
E
Blood vs ScWAT
Enrichement (%)
Angiogenesis
Interferon alpha response
Fatty acid metabolism
Mtorc1 signaling
Peroxisome
Oxidative phosphorylation
Adipogenesis
Hypoxia
G2m checkpoint
ithelial mesenchymal transition
F
Blood vs SkM
Enrichement (%)
Myc targets v2
Oxidative phosphorylation
Androgen response
Estrogen response late
Il2 stat5 signaling
Heme metabolism
Complement
Tnfa signaling via nfkb
Hypoxia
G2m checkpoint
G
ScWAT
Enrichement (%)
Blood vessel morphogenesis
Vasculature development
Tube morphogenesis
Tube development
Cell morphogenesis
rculatory system development
Embryo development
Morphogenesis
Cell motility
Macromolecule biosynthesis
H
SkM
Enrichement (%)
Isocitrate metabolic process
Angiogenesis
Succinyl coa metabolic process
Tricarboxylic acid metabolic process
Tricarboxylic acid cycle
Coronary vasculature development
Aorta development
Artery development
Fatty acid beta oxidation
Fatty acid catabolic process